Primary Biliary Cirrhosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market- NGM Biopharmaceuticals, Intercept Pharmaceuticals, Mirum Pharmaceuticals

Primary Biliary Cirrhosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market- NGM Biopharmaceuticals, Intercept Pharmaceuticals, Mirum Pharmaceuticals
DelveInsight Business Research LLP
DelveInsight’s “Primary Biliary Cirrhosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Primary Biliary Cirrhosis, historical and forecasted epidemiology as well as the Primary Biliary Cirrhosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Primary Biliary Cirrhosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Primary Biliary Cirrhosis, historical and forecasted epidemiology as well as the Primary Biliary Cirrhosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Primary Biliary Cirrhosis market report provides current treatment practices, emerging drugs, Primary Biliary Cirrhosis market share of the individual therapies, and current and forecasted Primary Biliary Cirrhosis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Primary Biliary Cirrhosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Primary Biliary Cirrhosis market.

Some of the key facts of the Primary Biliary Cirrhosis Market:

  • Affected individuals are usually in their fifth to seventh decades of life at the time of diagnosis, and 90% are women. Annual incidence is estimated between 0.7 and 49 cases per and prevalence between 6.7 and 940 cases per million population.

  • The pooled point-prevalence rate was 22.27 cases per 100,000 inhabitants (95% CI: 17.98–27.01), and the pooled annual incidence rate was 1.87 new cases per 100,000 inhabitants (95% CI: 1.46–2.34). In the subgroup analyses, we proved that a small part of the between-study heterogeneity is significantly associated with a history of being part of the Eastern Bloc

Got queries? Click here to know more about the Primary Biliary Cirrhosis Market Landscape

Primary Biliary Cirrhosis Overview

Primary Biliary Cirrhosis (MG) is an autoimmune disease that occurs when the immune system attacks the body’s own tissues. In MG, that attack interrupts the connection between nerve and muscle—the neuromuscular junction. MG is characterized mostly by autoantibodies against the acetylcholine receptor (AChR-Ab) or against a receptor-associated protein called muscle-specific tyrosine kinase (MuSK-Ab). The diagnosis of MG is mostly clinical, and laboratory investigations and procedures usually aid the clinician in confirming the clinical findings. The diagnosis of MG is done through various tests such as serological tests, edrophonium tests, ice-pack tests, imaging, and other laboratory test. Primary Biliary Cirrhosis remains one of the most challenging medical diagnoses due to its fluctuating character and the similarity of its symptoms to those of other disorders, as there are no international consensus guidelines. At present, the therapeutic market size of Primary Biliary Cirrhosis is mainly accounted by symptomatic treatments, including acetylcholinesterase inhibitors (Mestinon), short-term immunosuppressants (corticosteroids), long-term immunosuppressants (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid-acting short- term immunomodulators (intravenous immunoglobulin, plasma exchange), and long-term immunomodulatory procedures (thymectomy).

Primary Biliary Cirrhosis Epidemiology Segmentation

  • Primary Biliary Cirrhosis diagnosed cases 

  • Primary Biliary Cirrhosis incident cases  

  • Primary Biliary Cirrhosis prevalent cases 

  • Primary Billary Cirrhosis treatment cases 

Primary Biliary Cirrhosis Market Outlook 

The report’s Primary Biliary Cirrhosis (gMG) market outlook helps to better understand the historic, current and forecasted Primary Biliary Cirrhosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Primary Biliary Cirrhosis market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight. According to DelveInsight, the Primary Biliary Cirrhosis market in the 7MM is expected to grow steadily during the study period 2019–2032.

Learn more by requesting for sample @ Primary Biliary Cirrhosis Market Trends

 Primary Biliary Cirrhosis Key Companies

  • NGM Biopharmaceuticals 

  • Intercept Pharmaceuticals 

  • Mirum Pharmaceuticals 

  • Zydus Therapeutics 

  • And many others 

 

Primary Biliary Cirrhosis Therapies

  • Ustekinumab 90 mg

  • Elafibranor 80mg

  • Moexipril

  • Rituximab

And many others 

Table of Contents

  1.  Key Insights 

  2.  Report Introduction 

  3.  Executive Summary of Primary Biliary Cirrhosis     

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  The United States 

  7.  EU 5

  8.  Primary Biliary Cirrhosis Emerging Therapies

  9.  Primary Biliary Cirrhosis Market Outlook

  10.  Market Access and Reimbursement of Therapies

  11.  Market Drivers 

  12.  Market Barriers 

  13.  Appendix

  14.  Primary Biliary Cirrhosis   Report Methodology

  15.  DelveInsight Capabilities

  16.  Disclaimer

Click here to read more about Primary Biliary Cirrhosis Market 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services


Posted

in

by

Tags: